SGLT2 inhibitors (SGLT2i) and GLP-1 receptor antagonists (GLP1Ra) are widely used for the treatment of T2D and have been shown to have potent glucose-lowering and weight loss effects. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.